Els de Groot

1.1k total citations
8 papers, 941 citations indexed

About

Els de Groot is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Genetics. According to data from OpenAlex, Els de Groot has authored 8 papers receiving a total of 941 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Immunology and 5 papers in Genetics. Recurrent topics in Els de Groot's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and T-cell and B-cell Immunology (3 papers). Els de Groot is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and T-cell and B-cell Immunology (3 papers). Els de Groot collaborates with scholars based in Netherlands. Els de Groot's co-authors include Lucien A. Aarden, Gertjan Wolbink, Steven O. Stapel, L C Boeije, Alex de Vos, Maarten Helle, Michael T. Nurmohamed, Paul P. Tak, Ben A. C. Dijkmans and Alexandre E. Voskuyl and has published in prestigious journals such as Annals of the Rheumatic Diseases, European Journal of Immunology and Journal of Immunological Methods.

In The Last Decade

Els de Groot

8 papers receiving 902 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Els de Groot Netherlands	7	471	339	298	147	137	8	941
D Carthy United Kingdom	16	477 1.0×	584 1.7×	252 0.8×	88 0.6×	106 0.8×	23	1.1k
Jane E. Salmon United States	13	604 1.3×	355 1.0×	511 1.7×	63 0.4×	142 1.0×	19	1.1k
Schwartz Rs United States	12	321 0.7×	213 0.6×	302 1.0×	96 0.7×	108 0.8×	27	835
Hilde M. Dijstelbloem Netherlands	11	481 1.0×	190 0.6×	431 1.4×	87 0.6×	58 0.4×	14	976
Omri Snir Norway	20	741 1.6×	495 1.5×	424 1.4×	86 0.6×	167 1.2×	52	1.6k
Frank J. Waxman United States	15	648 1.4×	134 0.4×	272 0.9×	91 0.6×	321 2.3×	25	970
F. C. Breedveld Netherlands	15	438 0.9×	518 1.5×	197 0.7×	39 0.3×	82 0.6×	34	1.1k
Benjamin A. Fisher United Kingdom	11	274 0.6×	858 2.5×	339 1.1×	60 0.4×	73 0.5×	17	1.3k
Ruth Fritsch‐Stork Austria	23	859 1.8×	680 2.0×	167 0.6×	48 0.3×	153 1.1×	55	1.6k
John L. Abruzzo United States	15	235 0.5×	324 1.0×	216 0.7×	59 0.4×	102 0.7×	38	817

Countries citing papers authored by Els de Groot

Since Specialization

Citations

This map shows the geographic impact of Els de Groot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Els de Groot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Els de Groot more than expected).

Fields of papers citing papers by Els de Groot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Els de Groot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Els de Groot. The network helps show where Els de Groot may publish in the future.

Co-authorship network of co-authors of Els de Groot

This figure shows the co-authorship network connecting the top 25 collaborators of Els de Groot. A scholar is included among the top collaborators of Els de Groot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Els de Groot. Els de Groot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Schouwenburg, Pauline A. van, Lotte A van de Stadt, Rob N. de Jong, et al.. (2012). Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Annals of the Rheumatic Diseases. 72(1). 104–109. 157 indexed citations

2.

Schouwenburg, Pauline A. van, Lotte A van de Stadt, Rob N. de Jong, et al.. (2012). AB0055 Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization. Annals of the Rheumatic Diseases. 71. 640–640. 1 indexed citations

3.

Rispens, Theo, Els de Groot, Diana Wouters, et al.. (2011). Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing. Journal of Immunological Methods. 375(1-2). 93–99. 73 indexed citations

4.

Bartelds, G. M., Els de Groot, Michael T. Nurmohamed, et al.. (2010). Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Research & Therapy. 12(6). R221–R221. 56 indexed citations

5.

Wolbink, Gertjan, Marijn Vis, Willem F. Lems, et al.. (2006). Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis & Rheumatism. 54(3). 711–715. 378 indexed citations

6.

Lier, René A. W. van, et al.. (1991). T cell receptor/CD3 and CD28 use distinct intracellular signaling pathways. European Journal of Immunology. 21(7). 1775–1778. 33 indexed citations

7.

Helle, Maarten, L C Boeije, Els de Groot, Alex de Vos, & Lucien A. Aarden. (1991). Sensitive ELISA for interleukin-6. Journal of Immunological Methods. 138(1). 47–56. 226 indexed citations

8.

Aarden, L, et al.. (1977). Immunology of DNA. VI. The effect of mercaptans on IgG and IgM anti-dsDNA. Journal of Immunological Methods. 16(2). 143–152. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact